Loette

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loette

Defining Loette: Purpose and Pharmacological Class

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Tablet (Oral Contraceptive Tablet)
Pharmacological Class Hormonal Contraceptive
Common Use Pregnancy Prevention (Contraception)
Origin Synthetic (Synthetic Estrogen and Progestin)

Loette is a combination oral contraceptive tablet utilized exclusively for effective pregnancy prevention in women of reproductive potential. It is classified as a Hormonal Contraceptive, which falls within the pharmacological grouping of Sex Hormones and Modulators of the Genital System. Its fundamental purpose is reliable contraception, consistently established through clinical practice and widely supported by pharmacological studies. A review of combination oral contraceptives, including those with Ethinyl Estradiol and Levonorgestrel, consistently notes their efficacy as a primary method of birth control. This confirms that the medicine is established as a highly effective tool for managing reproductive health for individuals seeking fertility control.


Composition: Ethinyl Estradiol, Levonorgestrel, and Synthetic Origin

The composition of Loette relies on the synergistic action of the active ingredients, Ethinyl Estradiol and Levonorgestrel, presented in a monophasic tablet form. Ethinyl Estradiol serves as the estrogen component, and Levonorgestrel functions as the progestin component; both are produced via chemical synthesis, classifying them as synthetic steroid hormones. This formulation is characterized as a low-dose COC, representing a common refinement from earlier, higher-concentration formulations, and is clinically recognized for its reliable hormonal profile. The monophasic nature of the product, where the quantity of the synthetic estrogen and synthetic progestin remains constant across all active tablets within the monthly regimen, ensures predictable hormonal delivery. This constant dose simplifies the hormonal delivery and is a key feature of this specific type of oral contraceptive.


How Loette Prevents Pregnancy (High-Level Concept)

Loette prevents pregnancy through a coordinated triple-action mechanism that systemically influences the reproductive cycle. The primary mechanism is the inhibition of ovulation, blocking the release of an egg from the ovary. Concurrently, the hormonal action promotes cervical mucus thickening, which restricts sperm movement, and also induces endometrial alteration to the uterine lining. This collective inhibitory effect ensures the drug delivers its core general benefit: highly effective pregnancy prevention.

What side effects are possible with Loette?

Possible Side Effects and Safety Information

Serious and Clinically Significant Risks

Official regulatory labeling identifies serious, though rare, adverse reactions, primarily involving thromboembolic events. These include an increased risk of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as arterial thromboembolic events, such as myocardial infarction (heart attack) and stroke. The risk is highest during the first year of use and is significantly increased by smoking, especially in women over 35 years of age.

Other serious risks include the development of liver tumors (benign and malignant) and a potential association with cervical and breast cancer.

Common Adverse Reactions

The most frequently reported side effects are generally non-serious and often decrease over time. These include:

  • Very Common: Headache (including migraine), breakthrough bleeding, and spotting.
  • Common: Nausea, abdominal pain, breast pain or tenderness, weight changes, mood changes (including depression), and changes in menstrual flow.

Safety Restrictions and Contraindications

Loette is strictly contraindicated for individuals with a current or history of:

  • Thrombotic disorders (e.g., DVT, PE, stroke, or heart attack).
  • Severe, uncontrolled hypertension or certain heart valve disorders.
  • Known or suspected breast cancer or other estrogen- or progestin-sensitive cancers.
  • Liver disease, liver tumors, or cholestatic jaundice.
  • Migraine with focal neurological symptoms.
  • Concurrent use with certain Hepatitis C virus (HCV) drug combinations (ombitasvir/paritaprevir/ritonavir and dasabuvir).

Note: Discontinuation is officially recommended at least four weeks before and for two weeks following major surgery or prolonged immobilization due to increased blood clot risk.

Overdose and Emergency Response

Overdose and When to Seek Help

Acute ingestion of excessive doses of Loette (Ethinyl Estradiol/Levonorgestrel) is classified by regulatory documents as having low acute toxicity. Consequently, serious adverse effects are not typically expected following a single, acute overdose.

The documented clinical manifestations primarily involve the gastrointestinal and reproductive systems:

  • Nausea and Vomiting are the most common reported signs.
  • Withdrawal bleeding (or breakthrough bleeding) is a specific hormonal manifestation documented in females and adolescents following acute ingestion.

Emergency Actions and Supportive Management

Immediate medical attention is strictly required following any suspected overdose above the prescribed amount. It is mandated to contact a poison control center immediately for professional guidance and assessment.

Management is strictly limited to symptomatic and supportive treatment. This procedural approach is officially described because no specific antidote is known for this hormonal product. Clinical observation and monitoring may be necessary until the individual's condition is confirmed to be stable and symptoms, if any, have resolved. The requirement to seek medical advice applies even if the patient remains asymptomatic.

Therapeutic Uses of Loette

What Loette Treats: Main Uses and Benefits

Loette is commonly used as a contraceptive to prevent pregnancy. This medication is relevant for easing the symptomatic burden across domains where additional symptomatic support is needed. It helps address condition categories that involve moderate acne vulgaris, and it is applied in addressing symptoms related to menstrual health, such as painful cramps (dysmenorrhea) and cycle irregularity. Its consistent daily use may assist with aspects of family planning, and it contributes to improved comfort during symptomatic periods.

The use of the medication may assist with maintaining functional stability during symptomatic periods:

“May help patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Acne This oral medication is generally applied in scenarios where symptoms related to moderate facial acne become more noticeable, and may assist with providing supportive relief for these visible manifestations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility profile for Loette (Levonorgestrel and Ethinyl Estradiol) is strictly defined by regulatory authorities and is indicated for postmenarchal females of reproductive potential. The medicine is subject to several official contraindications that strictly prohibit its use based on high-risk factors.

Contraindicated populations include women over 35 years of age who smoke. Use is also prohibited for females with current or a history of thrombotic disorders such as deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction. Other absolute exclusions cover individuals with migraines with aura, current or history of breast cancer, active liver disease, severe cirrhosis, or liver tumors.

In terms of status, the medicine is contraindicated if pregnancy is known or suspected and is not recommended for lactating women. Loette must be temporarily discontinued at least four weeks before and through two weeks after major surgery or during periods of prolonged immobilization. The medicine is not indicated for pre-menarchal children or postmenopausal women.

What should I know about interactions with other medicines?

The official interaction profile for Loette is defined by several categories of documented pharmacokinetic and pharmacodynamic interactions. Certain medicinal combinations are formally prohibited. Co-administration with Hepatitis C drug regimens containing Ombitasvir, Paritaprevir, and Ritonavir is contraindicated due to the documented risk of liver enzyme elevation. Similarly, oral Tranexamic Acid is contraindicated based on a pharmacodynamic interaction that significantly increases the risk of thromboembolism.

The largest group of documented interactions involves metabolic pathways. Drugs that induce enzymes, specifically CYP3A4 inducers (such as Rifampin, Phenytoin, or Carbamazepine), are known to decrease the plasma concentrations of the contraceptive components, leading to potential loss of efficacy. Conversely, agents that act as CYP3A inhibitors (including certain antifungals like Itraconazole) may increase the systemic exposure of the contraceptive steroids.

Exposure can also be altered by non-enzyme agents. Certain statins (like Atorvastatin and Rosuvastatin) are documented to increase Ethinyl Estradiol exposure by up to 25%. The administration of Colesevelam requires a specific separation of 4 or more hours to mitigate a documented decrease in Ethinyl Estradiol systemic exposure. A formal use restriction also applies to patients: use of this medicine is contraindicated in females 35 years of age or older who smoke, due to the critical interaction of smoking with the drug's thrombotic risk profile.

Mechanism of Action

Primary Mechanism: HPO Axis Suppression and Ovulation Blockade

The two active ingredients act as agonists at the Estrogen and Progesterone Receptors, establishing a non-physiological negative feedback signal that primarily acts on the brain's control centers. This signal suppresses the release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), which are necessary to trigger the maturation and release of an egg (ovulation). This central suppression is the primary mechanism, resulting in a non-ovulatory state.


Secondary Mechanism: Peripheral Tissue Modulation

Complementing the central action, the progestin component, Levonorgestrel, induces structural and functional changes in peripheral reproductive tissues. The mucus in the cervix becomes highly viscous and dense, which creates a physical barrier that restricts the movement of sperm. Additionally, the lining of the uterus (endometrium) is altered, which reduces its receptivity. These peripheral effects provide a secondary physiological barrier, reinforcing the primary suppressive action through multiple co-occurring mechanisms.

Dosage and Administration Information

How Loette is Used: Official Administration Guidelines

This section outlines the documented administration principles and standardized dosing regimens for the combination oral contraceptive Loette (levonorgestrel 0.10 mg and ethinyl estradiol 0.02 mg).


Administration Scope

Instruction Detail
Route of Administration The approved route is oral (by mouth).
Dosing Schedule The standard regimen involves one tablet daily, structured as a 28-day cycle containing 21 active tablets followed by 7 inactive (placebo) tablets.
Frequency and Timing One tablet must be taken at the same time every day, ensuring the interval between doses does not exceed 24 hours.
Start Date Protocols Initiation may use a Day 1 Start (first day of menses) or a Sunday Start. The Sunday Start requires an additional non-hormonal method of contraception for the first 7 days of the first cycle.
Missed-Dose Principle If one active tablet is missed by more than 12 hours, the last missed tablet is taken immediately, and an additional non-hormonal contraceptive method is required for the following 7 days.
Population Rule For non-breastfeeding women, the medication should not be initiated earlier than four weeks post-delivery due to procedural constraints related to the post-partum period.

Resulting Procedural Structure

The standard protocol establishes a strict oral, daily, cyclic administration protocol for Loette. This structure defines the precise quantity and mandated order of the 21 active and 7 inactive tablets within the 28-day cycle, requiring the next pack to be started immediately after the previous one finishes. These instructions delineate the approved methods for initiating treatment and provide the steps for managing any deviation from the 24-hour dosing schedule.

Recent Clinical Evidence

Research evidence / Overview of Studies for Loette

Evidence for Use in Pregnancy Prevention (Contraception)

The primary evidence for Loette comes from large-scale, often open-label clinical studies and Randomized Controlled Trials (RCTs). These studies were used in research exploring reproductive cycle characteristics. Researchers monitored outcomes related to the prevention of pregnancy, often tracking the number of pregnancies that occurred over a specific period of time (e.g., the Pearl Index). Studies primarily focused on healthy women of reproductive potential, generally spanning the age range from postmenarchal status up to 49 years.

Research describes changes measured during the study period related to cycle characteristics. Studies reported patterns observed in the consistency, duration, and intensity of withdrawal bleeding among participants. The findings describe group patterns measured under the specific conditions of the trial. Long-term outcomes characterizing patterns observed beyond one year are not always well characterized in controlled, initial trials; evidence over extended periods often stems from broader observational studies.


Evidence for Use in Moderate Acne Vulgaris

Research has explored the application of this hormonal combination for moderate facial acne. The key evidence is derived from Randomized, Double-Blind, Placebo-Controlled Clinical Trials. Researchers focused on outcomes linked to inflammatory or irritative states, such as quantifying changes in the number of total, inflammatory, and non-inflammatory facial lesions.

Studies report how symptoms were measured in the observed populations, noting measurements taken over a defined interval, typically six months. Clinicians also used standardized Global Assessment Scales in trials assessing short-term or episodic symptom patterns to rate the overall condition of the skin. Data are still emerging regarding the long-term durability of the measured effects after the use of the product is stopped.


Evidence Related to Menstrual Symptoms (Dysmenorrhea and Cycle Regularity)

Loette was evaluated in research exploring outcomes related to physical discomfort, specifically concerning painful cramps (dysmenorrhea) and menstrual cycle predictability. Evidence in this area is largely gathered from systematic reviews and meta-analyses that pool data from numerous trials involving combined oral contraceptives as a class. Findings describe patterns observed in the studies, including measurements of pain severity scores in the aggregated data. However, the specific evidence for this exact low-dose ethinyl estradiol/levonorgestrel formulation on dysmenorrhea is often limited and aggregated with data from the broader COC class.


What is Still Uncertain in the Research Record

While substantial evidence exists for the core uses of combined oral contraceptives, certain research limitations are noted. Comparative evidence is lacking for a direct head-to-head assessment of this specific low-dose formulation against the large number of other hormonal contraceptives currently available. Furthermore, follow-up durations were limited in the primary controlled trials, meaning the long-term effects are not fully established based on controlled study designs. The results apply only to the populations studied and do not determine whether an individual will respond similarly.

Key Studies & References

  1. LOETTE* 21 TABLETS - Regulatory Document (Levonorgestrel and Ethinylestradiol)
  2. Levonorgestrel and Ethinylestradiol Tablets IP - LOETTE - Pfizer Labeling
  3. Ethinyl Estradiol and Levonorgestrel (Oral Contraceptives): MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Loette (FAQ)

Q: How quickly does Loette start working?

A: The time it takes for Loette to provide effective pregnancy prevention depends on the initiation method used. Official guidelines describe starting on the first day of the menstrual period (Day 1 Start) as providing immediate protection. The Sunday Start protocol, as described in regulatory documents, involves the use of an additional non-hormonal contraceptive method for the first 7 days of the first cycle.

Q: What should be done if a dose of Loette is missed?

A: Official documents provide detailed protocols for managing missed doses, including the specific actions required for a single missed active tablet and protocols for missing multiple active tablets. For instance, if a tablet is missed by more than 12 hours, specific steps regarding taking the tablet and using a backup method are outlined. These protocols vary depending on the number of tablets missed and the week of the cycle; therefore, referring to the detailed patient information leaflet is necessary for accurate guidance.

Q: Can Loette be used while breastfeeding?

A: Regulatory documents state that using combined oral contraceptives, such as Loette, is not recommended while actively breastfeeding. This is because official information indicates that the hormones may reduce the quantity of breast milk produced, and the medicine is secreted into breast milk. Additionally, the drug should not be initiated earlier than four weeks after delivery.

Q: What happens when you stop taking Loette?

A: When use is discontinued, a person's natural menstrual cycle will eventually resume. Official information notes that some women may experience amenorrhea (absence of menstruation) or oligomenorrhea (infrequent menstruation) after discontinuation, particularly if these conditions were noted before starting the medication.

Q: Are there different dose strengths of Loette available?

A: The specific drug Loette is a single, fixed-dose product containing 0.10 mg of levonorgestrel and 0.02 mg of ethinyl estradiol. Regulatory documents confirm that this is a monophasic formulation, meaning the hormone dose is the same in every active pill in the pack. Other low-dose combined contraceptives exist, but they are not different dose strengths of a product branded as Loette.

Q: Is it common to have lighter or shorter periods while on Loette?

A: Official product information lists changes in menstrual flow as a common adverse reaction. Research studies examining reproductive cycle characteristics often describe patterns observed in the consistency, duration, and intensity of withdrawal bleeding among participants, and this can result in lighter or shorter bleeding compared to a natural period.

Q: Does Loette work differently than other types of birth control pills?

A: Loette is classified as a Combined Oral Contraceptive (COC) because it contains both estrogen and progestin. Its main function is the inhibition of ovulation (blocking egg release), which is reinforced by thickening the cervical mucus and altering the uterine lining. The presence of both hormones allows for the dual action of ovulation inhibition and peripheral effects, which is the defining characteristic of this type of contraceptive.

Q: Can taking Loette cause changes in weight?

A: Official regulatory labels list changes in weight (which can be either an increase or a decrease) as a common adverse reaction associated with the use of Loette. This is a common pattern observed in clinical trials, though the degree of change can vary widely among individuals.

Q: How does Loette affect your menstrual cycle?

A: Loette works to regulate the cycle into a predictable 28-day pattern. The active tablets lead to hormonal suppression, and the inactive tablets allow for a scheduled withdrawal bleed. Research indicates this pattern is often more consistent and predictable than a natural, unregulated cycle.

Q: Does Loette have a generic version available?

A: Yes, the specific combination and dose of its active ingredients, levonorgestrel 0.10 mg and ethinyl estradiol 0.02 mg, are widely available as generic medications. These generics contain the same active ingredients and strength as the brand-name product.

Q: Is there any information about Loette's effect on mood?

A: Official labeling lists mood changes (including depression) as a common adverse reaction. Regulatory information also advises that females who have a history of depression should be carefully observed when taking this medication.

Q: Does taking Loette cause changes in acne?

A: Research evidence states that the combination is used for the treatment of moderate acne vulgaris. In studies examining this effect, the formulation was used for the treatment of moderate acne vulgaris, focusing on outcomes such as reducing the number of facial lesions.

Q: Can Loette be used by someone with a history of migraines?

A: Official labeling states that the drug is strictly contraindicated for females who experience headaches with focal neurological symptoms or have migraine headaches with aura. Furthermore, women over age 35 who have any migraine headaches (with or without aura) are also advised against using this medication.

Q: Are there any specific lifestyle habits that can affect how Loette works?

A: Regulatory warnings specifically identify cigarette smoking as a lifestyle habit that interacts with the drug's safety profile. Smoking is identified as increasing the risk of serious cardiovascular events, and this is a formal use restriction, particularly in women over 35 years of age.

Q: What is the risk of developing high blood pressure while on Loette?

A: Official documents indicate that the drug can be associated with an increase in blood pressure. The product is strictly contraindicated for females with severe, uncontrolled hypertension. Regulatory guidance advises clinicians to monitor blood pressure during routine visits and consider stopping the medication if blood pressure rises significantly.

Q: Is stomach upset a common initial side effect of Loette?

A: The side effects profile lists nausea and abdominal pain as common adverse reactions. These types of gastrointestinal symptoms are generally common when first starting combined oral contraceptive pills, but usually lessen over time.

Q: Does Loette impact fertility later on?

A: Studies and health authority overviews indicate that combination hormonal methods, including Loette, do not seem to cause long-term delays in the return of fertility after discontinuation. Research suggests that most women who stop using the pill to become pregnant achieve pregnancy within 12 months.

Q: Is 'Loette' the same drug as 'Alesse'?

A: The drug Loette and the product Alesse are considered brand names for the same formulation. They are pharmacologically equivalent formulations, containing the identical dose of 0.10 mg levonorgestrel and 0.02 mg ethinyl estradiol.

Q: Can taking multiple packs of Loette consecutively delay my period?

A: The standard regimen includes 7 inactive (placebo) tablets to schedule a monthly withdrawal bleed. By intentionally skipping the placebo week and immediately starting a new pack of active tablets, a person can sustain hormone levels. This practice is recognized as a method to suppress the withdrawal bleed.

Q: Can people with diabetes use Loette?

A: Official contraindications advise against using the drug in certain high-risk groups of diabetic women. The medication is strictly contraindicated for diabetic women over age 35, or for females who have diabetes with hypertension, vascular disease, or other organ damage, or diabetes of a long duration (over 20 years).

Q: How does the concentration of hormones in Loette compare to other low-dose options?

A: Loette contains 0.02 mg of ethinyl estradiol, which is the concentration used to define it as a low-dose formulation. This dosage is a standard quantitative measure that is significantly lower than older combined oral contraceptives, which often contained 0.05 mg or more of ethinyl estradiol.

Q: Is there a link between Loette and changes in vision?

A: Regulatory warnings mention an association with a risk of visual changes. This includes symptoms such as loss of vision, proptosis (bulging eye), diplopia (double vision), and retinal vascular lesions. Official advice recommends seeking immediate attention if a person experiences any unexplained partial or complete loss of vision.

Q: Does sun exposure or heat affect Loette's effectiveness?

A: Official storage instructions require that the medication be kept away from excessive heat and direct light. Furthermore, regulatory warnings advise females with a history of chloasma (darkening of skin patches) to avoid exposure to the sun or ultraviolet radiation while taking the medication.

How should Loette be stored and disposed of?

How to Store and Dispose of Loette (Levonorgestrel and Ethinyl Estradiol Tablets)

Official labeling defines strict conditions for storing and handling Loette to maintain its stability.

Storage Requirements

Storage Condition Type Requirement
Temperature Range Store at Controlled Room Temperature of 20°C to 25°C (68°F to 77°F).
Protection Store away from heat, moisture, and direct light. Do not freeze.
Packaging Keep the tablets in the original blister pack until use. Do not use if the seal is compromised or broken.
Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

When the product is expired or no longer needed, it must be safely discarded. Official guidelines require consulting a pharmacist for instructions on the proper method for disposing of any leftover medicine, in accordance with local and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loette found in:

A-Z Index: